Non-peptide BDNF Mimetics for TrkB Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents based on neurotrophins face challenges such as poor stability, low oral bioavailability, restricted central nervous system penetration, and ethical concerns, along with the difficulty of producing sufficient quantities, limiting their effectiveness in treating neurological and non-neurological disorders.
Innovation Solution
Development of small molecule non-peptidyl compounds with binding and/or modulation specificity for the TrkB receptor, optionally in combination with TrkA or TrkC receptors, to mimic key regions of neurotrophin proteins and activate the TrkB receptor, thereby treating various disorders without the adverse interactions with p75 NTR and sortilin receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotrophins are used as therapeutic agents, then neural survival and function are promoted, but stability and serum half life are poor
Solution Approach 1:
The patent creates synthetic peptide copies of the BDNF neurotrophin that replicate its biological function of promoting neural survival while improving stability. These synthetic peptides are designed to mimic the key functional regions of BDNF, allowing them to bind to TrkB receptors and activate downstream signaling pathways without the instability issues of natural neurotrophins.
Solution Approach 2:
The patent modifies the molecular parameters of the original BDNF protein by creating truncated versions that retain functional activity. Specifically, the invention uses peptides corresponding to loops 2 and 4 of BDNF, which are sufficient to activate TrkB receptors but have improved pharmacological properties including enhanced stability and reduced molecular weight for better tissue penetration.
2Reliability
If neurotrophins are administered therapeutically, then neural function is enhanced, but oral bioavailability is low
Solution Approach 1:
The patent divides the large BDNF protein (120 amino acids) into smaller functional segments, specifically loops 2 and 4, which contain the critical receptor-binding information. This segmentation creates peptides of reduced size that can better penetrate biological barriers and achieve improved oral bioavailability while maintaining the ability to activate TrkB receptors and enhance neural function.
3Reliability
If neurotrophins are used for treatment, then neural survival is promoted, but central nervous system penetration is restricted
Solution Approach 1:
The patent extracts only the essential functional portions of the BDNF molecule—specifically loops 2 and 4—that are responsible for TrkB receptor activation. By removing non-essential portions of the protein, the invention creates smaller peptides that can more effectively penetrate the central nervous system while retaining the ability to promote neural survival through TrkB signaling.
4Reliability
If neurotrophins are administered, then neural effects are achieved, but adverse effects through p75 NTR and sortilin receptors occur
Solution Approach 1:
The patent applies local quality by designing peptides with specific structural features that match only the TrkB receptor binding site. The synthetic peptides corresponding to loops 2 and 4 of BDNF are configured to interact selectively with TrkB, while their modified structure prevents binding to p75 NTR and sortilin receptors, thereby achieving neural effects without the adverse side effects associated with non-selective receptor activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule compounds effectively alleviate neural degeneration, promote neural survival, and enhance neural function, offering a more stable and effective treatment option for a range of disorders, including neurological and non-neurological conditions, while minimizing adverse effects.
Implementation Method 1
small molecule compounds with binding and/or modulation specificity for the TrkB receptor... effectively alleviate neural degeneration, promote neural survival, and enhance neural function
Data Source
Figure 1
Figure 2
AI summary
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.